MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
205.91%
Quick Ratio
205.91%
Cash Ratio
199.09%
Debt to Asset Ratio
48.59%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Right-of-use asset
    • Other assets
Liabilities Breakdown
    • Additional paid-in capital
    • Accumulated deficit
    • Clinical trial accrued liabiliti...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
12,634
13,731
10,278
14,277
Prepaid expenses and other current assets
433
431
597
369
Total current assets
13,067
14,162
10,875
14,646
Property and equipment, net
8
12
17
22
Right-of-use asset
175
193
210
76
Other assets
21
21
21
21
Total assets
13,271
14,388
11,123
14,765
Accounts payable
921
1,007
1,060
2,599
Clinical trial accrued liabilities
2,825
627
79
1,562
Accrued expenses and other current liabilities
606
456
993
711
Warrant liabilities
23
19
136
167
Related party payable
1,897
3,012
3,312
3,316
Lease liability, short-term
74
71
68
79
Total current liabilities
6,346
5,192
5,648
8,434
Lease liability, long-term
103
123
142
-
Total liabilities
6,449
5,315
5,790
8,434
Common stock, 0.001 par value per share, 100,000,000 shares authorized as of june 30, 2026 and december 31, 2025 6,575,656 and 2,308,294 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
7
5
2
24
Additional paid-in capital
164,784
161,721
154,161
153,207
Accumulated deficit
-157,969
-152,653
-148,830
-146,900
Total stockholders' equity
6,822
9,073
5,333
6,331
Total liabilities and stockholders' equity
13,271
14,388
11,123
14,765
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$12,634K (-28.17%↓ Y/Y)Prepaid expenses andother current assets$433K (-40.36%↓ Y/Y)Total current assets$13,067K (-28.65%↓ Y/Y)Right-of-use asset$175K (82.29%↑ Y/Y)Other assets$21K (0.00%↑ Y/Y)Property and equipment,net$8K (-70.37%↓ Y/Y)Total assets$13,271K (-28.11%↓ Y/Y)Total liabilities andstockholders' equity$13,271K (-28.11%↓ Y/Y)Total stockholders'equity$6,822K (-29.11%↓ Y/Y)Total liabilities$6,449K (-27.01%↓ Y/Y)Accumulated deficit-$157,969K (-10.07%↓ Y/Y)Additional paid-in capital$164,784K (7.62%↑ Y/Y)Total currentliabilities$6,346K (-28.05%↓ Y/Y)Lease liability,long-term$103K (586.67%↑ Y/Y)Common stock, 0.001 parvalue per share,...$7K (-70.83%↓ Y/Y)Clinical trial accruedliabilities$2,825K (93.10%↑ Y/Y)Related party payable$1,897K (-48.38%↓ Y/Y)Accounts payable$921K (-67.97%↓ Y/Y)Accrued expenses andother current...$606K (-0.66%↓ Y/Y)Lease liability,short-term$74K (-10.84%↓ Y/Y)Warrant liabilities$23K (-79.82%↓ Y/Y)

MetaVia Inc. (MTVA)

MetaVia Inc. (MTVA)